News
-
Qualcomm subsidiary Qualcomm Life will design a disposable module for the Breezhaler DPI that will sense and report inhaler usage data for Novartis’s Breezhaler COPD products, including Ultibro, Seebri, and Onbrez. The Breezhaler DPIs are… Read more . . .
-
Sanofi will return development and commercialization rights for Afrezza inhaled insulin to MannKind after disapponting sales, and MannKind says that it is considering strategic options for the product. Afrezza was approved by the FDA in… Read more . . .
-
Cipla has announced the launch of a mobile app called “My Breathefree,” which is intended to serve as a “virtual caregiver” for asthma patients in India. The app includes video demonstrations of correct use for… Read more . . .
-
Discovery Laboratories has announced the initiation of a Phase 2b trial of Aerosurf aerosolized KL4 surfactant to treat respiratory distress syndrome (RDS) in premature infants. The trial, which is expected to enroll up to 250… Read more . . .
-
Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma’s SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a… Read more . . .
-
GlaxoSmithKline has recalled two lots of Ventolin HFA metered dose inhalers totaling 128,704 inhalers, according to an FDA enforcement report. The company initiated the voluntary recall on December 3, 2015 due to concerns about insufficient… Read more . . .
-
Welcoming over 600 attendees to the Edinburgh International Conference Centre, conference chair Gary Pitcairn opened the meeting on December 9, 2015 by noting the 20% increase in attendance from DDL 25 and suggesting that next… Read more . . .
-
The FDA has granted orphan drug designation to Neurelis’s lead product, NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients, the company said. Biotie paid $1 million for an option to… Read more . . .
-
Alexza Pharmaceuticals has announced interim results from a Phase 2a study of AZ-002 inhaled alprazolam in epilepsy patients. Dose-related decreases in mean standardized photosensivity range (SPR), the study’s primary endpoint, were noted 2 minutes post… Read more . . .
-
A study published online in the journal Diabetes Care on December 17, 2015 demonstrated non-inferiority of intranasal glucagon to intramuscular glucagon for the treatment of insulin-induced hypoglycemia in type 1 diabetes patients. The study found… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.